| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 48,450 | 48,850 | 22:50 | |
| 48,550 | 48,750 | 21:57 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 53,90 | 55 | |||
| 52,00 | 25 | |||
| 51,80 | 15 | |||
| 51,50 | 23 | |||
| 50,90 | 100 | |||
| 50,10 | 325 | |||
| 49,900 | 150 | |||
| 49,500 | 40 | |||
| 48,850 | 167 | |||
| 48,750 | 167 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/bbza.htm [/URL] | ||||
| 167 | 48,550 | |||
| 167 | 48,500 | |||
| 30 | 45,000 | |||
| 120 | 43,000 | |||
| 150 | 42,500 | |||
| 70 | 30,200 | |||
| 10 | 30,000 | |||
| 50 | 27,650 | |||
| 75 | 27,550 | |||
| 50 | 26,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 889 | 1,200 | 1.067 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:16:54 | 49,050 | 68 |
| 17:11:29 | 48,900 | 250 |
| 17:01:35 | 48,950 | 251 |
| 16:53:31 | 49,050 | 19 |
| 16:53:31 | 49,050 | 122 |
| 16:53:31 | 49,050 | 300 |
| 16:53:31 | 49,050 | 75 |
| 16:53:31 | 49,050 | 84 |
| 16:49:57 | 49,050 | 158 |
| 16:38:57 | 48,950 | 20 |
| 16:30:57 | 49,100 | 292 |
| 16:25:14 | 48,850 | 50 |
| 16:23:43 | 48,800 | 244 |
| 16:23:43 | 48,850 | 456 |
| 16:11:55 | 48,950 | 281 |
| 16:10:44 | 49,050 | 204 |
| 16:00:51 | 49,200 | 36 |
| 16:00:04 | 48,900 | 75 |
| 15:54:48 | 48,950 | 91 |
| 15:52:47 | 49,050 | 92 |
| Tagesumsatz Xetra | +1,800 +3,83 % | 14.893 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12.25 | Jade Biosciences secures $45 million in private placement from BB Biotech | 122 | Investing.com | ||
| 03.11.25 | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | 2.236 | PLATOW Börse | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| 28.10.25 | BB Biotech - Turning milestones into momentum | 844 | Edison Investment Research | BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0%... ► Artikel lesen | |
| BB BIOTECH Aktie jetzt für 0€ handeln | |||||
| 28.10.25 | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | 697 | EQS Group (EN) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Oct-2025 / 12:15 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| 25.10.25 | BB Biotech & Evotec: Biotech immer noch historisch "billig"? Und die bessere Aktie ist? | 3.551 | Nebenwerte Magazin | BB Biotech & Evotec: Zwei Aktien, die ein klar unterschiedliches Risikopotential bieten. Deshalb die Frage: Wird höheres Risiko durch höhere Gewinnchncen ausgeglichen? Ein Aktienvergleich für Anleger... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 20:10 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.01.2026 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 07.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.01.2026ISIN NameNL0015002CX3 QIAGEN... ► Artikel lesen | |
| 20:38 | Scott+Scott Attorneys at Law LLP: Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT) | Newsfile | New York, New York--(Newsfile Corp. - January 7, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics... ► Artikel lesen | |
| 14:36 | FibroBiologics, Inc.: FibroBiologics CEO Issues Letter to Shareholders | GlobeNewswire (Europe) | HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development... ► Artikel lesen | |
| 19:06 | Swedish Orphan Biovitrum AB: Sobi to advance Gamifant (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data | PR Newswire | STOCKHOLM, Jan. 7, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven... ► Artikel lesen | |
| 16:55 | XETR DELETION OF INSTRUMENTS FROM XETRA - 07.01.2026 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 07.01.2026.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 07.01.2026.ISIN NameDE000A2QEFA1 The Platform Group... ► Artikel lesen |